Karen L. Marquis - Concepedia

Author

Karen L. Marquis

Princeton University

Also Known As

K L Marquis, K. L. MARQUIS, K. L. Marquis, K. Marquis, K.L. Marquis, Karen L Marquis, Karen L. Marquis, Karen Marquis

Publications

3.3K

Citations

H-Index

Concepts

All Affiliations

Princeton University Women's Health Research Institute University of Maryland, Baltimore CNS Research (United States)Pfizer (United States)

About

Karen L. Marquis is an author at Princeton University specializing in medicine, pharmacology, and neuropharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	31	1.9K
2	Social Sciences	15	16	1.3K
3	Natural Sciences	6	6	242
4	Engineering	1	1	10
5	Health Sciences	1	1	42

Karen L. Marquis

Publications

Citations

H-Index

Page 1

	Year	Citations
Activation of estrogen receptor-β regulates hippocampal synaptic plasticity and improves memory Feng Liu, Mark L. Day, Luis C Muñiz, Nature Neuroscience Synaptic PlasticityCognitive ScienceMedicineHormonal ReceptorNeuroendocrine Mechanism	2008	496
Phosphodiesterase 10A Inhibitor Activity in Preclinical Models of the Positive, Cognitive, and Negative Symptoms of Schizophrenia Steven M. Grauer, Virginia Pulito, Rachel L. Navarra, Journal of Pharmacology and Experimental Therapeutics	2009	265
Schizophrenia-Related Neural and Behavioral Phenotypes in Transgenic Mice Expressing Truncated<i>Disc1</i> Sanbing Shen, Bing Lang, Chizu Nakamoto, Journal of Neuroscience	2008	253
Acute γ-Secretase Inhibition Improves Contextual Fear Conditioning in the Tg2576 Mouse Model of Alzheimer's Disease Thomas A. Comery, Robert Martone, Suzan Aschmies, Journal of Neuroscience Acute TreatmentNeuropsychologyAffective NeuroscienceNeurochemical BiomarkersSwedish Mutation	2005	212
ADX47273 [S-(4-Fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: A Novel Metabotropic Glutamate Receptor 5-Selective Positive Allosteric Modulator with Preclinical Antipsychotic-Like and Procognitive Activities Feng Liu, Steve Grauer, Cody Kelley, Journal of Pharmacology and Experimental Therapeutics	2008	181
WAY-163909 [(7 bR,10 aR)-1,2,3,4,8,9,10,10 a-Octahydro-7 bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A Novel 5-Hydroxytryptamine 2C Receptor-Selective Agonist with Preclinical Antipsychotic-Like Activity Karen L. Marquis, Annmarie L. Sabb, Sheree F. Logue, Journal of Pharmacology and Experimental Therapeutics	2006	145
Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist Robert H. Ring, Lee E. Schechter, Sarah K. Leonard, Neuropharmacology Molecular PharmacologyBehavioral NeuroscienceMedicineFunctional SelectivityBehavioral Pharmacology	2009	145
Lecozotan (SRA-333): A Selective Serotonin 1A Receptor Antagonist That Enhances the Stimulated Release of Glutamate and Acetylcholine in the Hippocampus and Possesses Cognitive-Enhancing Properties Lee E. Schechter, Daniel L. Smith, Sharon Rosenzweig‐Lipson, Journal of Pharmacology and Experimental Therapeutics	2005	130
Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodents Sharon Rosenzweig‐Lipson, Annmarie L. Sabb, Gary Stack, Psychopharmacology Molecular PharmacologyPsychiatryFunctional SelectivityAntidepressant-like EffectsMedicine	2007	100
Pharmacological comparison of muscarinic ligands: Historical versus more recent muscarinic M1-preferring receptor agonists Julia Heinrich, John A. Butera, Tikva Carrick, European Journal of Pharmacology Historical VersusFunctional SelectivityMedicineMechanism Of ActionReceptor (Biochemistry)	2009	98

Page 1